Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Kymera's CEO Sold $6 Million in Stock After a 170% Run
According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock holdings by 7%, leaving a residual direct position of 667,000 shares.
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5bn cash position. KT-621, an oral STAT6 degrader for atopic dermatitis, has accelerated Phase 2b timelines with topline data now expected by year-end 2026. KT-621's oral administration and promising early efficacy/safety data position KYMR to challenge injectable incumbents in a multi-billion dollar market.
Kymera: Building Toward A Defining 2H26 Moment
Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection point. KT-621, a first-in-class oral STAT6 degrader, targets large, expanding markets in atopic dermatitis and other type 2 inflammatory diseases. Rapid trial enrollment, a strong balance sheet ($1.55B cash), and external validation position KYMR for potential high-value partnerships and lifecycle expansion.
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.
